High plasma creatine kinase: Review of the literature and proposal for a diagnostic algorithm

Neurological Sciences

Volumn 27, Issue 5, 2006, Pages 303-311

  Morandi, L ^a   Angelini, C ^b   Prelle, A ^c   Pini, A ^d   Grassi, B ^c   Bernardi, G ^a   Politano, L ^e   Bruno, C ^f   De Grandis, D ^g   Cudia, P ^g   Citterio, A ^h  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f G GASLINI INSTITUTE   (Italy)

^g S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^h C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Asymptomatic hyperCKaemia; Diagnostic protocol; Normal neurological examination

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARTEOLOL; CERVISTATIN; CLOZAPINE; CREATINE KINASE; CYCLOSPORIN; DIGOXIN; DYSTROPHIN; FIBRIC ACID DERIVATIVE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; MACROLIDE; PINDOLOL; PYRROLE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; UBIDECARENONE; UNCLASSIFIED DRUG; WARFARIN;

CLINICAL PROTOCOL; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG POTENTIATION; DRUG WITHDRAWAL; ELECTROMYOGRAM; ENZYME ACTIVITY; ENZYME ASSAY; ESSENTIAL HYPERTENSION; EXERCISE; HUMAN; HYPONATREMIA; HYPOTHYROIDISM; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCLE INJURY; MUSCULAR DYSTROPHY; MYALGIA; MYOGLOBINURIA; MYOPATHY; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASE; NEUROPHYSIOLOGY; PHYSICAL ACTIVITY; PSYCHOSIS; RACE DIFFERENCE; REFERENCE VALUE; REVIEW; RHABDOMYOLYSIS; SEX DIFFERENCE; SIDE EFFECT; SYSTEMIC DISEASE;

ALGORITHMS; CREATINE KINASE; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMANS; NEUROMUSCULAR DISEASES; REVIEW LITERATURE;

EID: 37849189496     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-006-0701-0     Document Type: Review

References (75)

1. Rowland LP, Willner J, Di Mauro S, Miranda A (1980) Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C, Danieli GA, Fontanri D (eds) Muscular dystrophy - advances and new trends. Excerpta Medica, Amsterdam, pp 3-13.
2. Afifi AK (1998) Idiopathic high plasma CK revisited. J Child Neurol 13:251-252
3. Zatz M, De Paula F, Starling A, Vainzof M (2003) The 10 autosomal recessive limb-girdle muscular dystrophy. Neuromusc Dis 13:532-544
4. Ozawa E, Nishino I, Nonaka I (2001) Sarcolemmopathy: Muscular dystrophies with cell membrane defects. Brain Pathol 11:218-230
5. Brown SC, Muntoni F, Sewry CA (2001) Non-sarcolemmal muscular dystrophies. Brain Pathol 11:193-205
6. Reijneveld JC, Notermans LC, Linssen WH, Wokke JH (2000) Benign prognosis in idiopathic hyper-CK-aemia. Muscle Nerve 23:575-579
7. Reijneveld JC, Noermans LC, Linssen WH et al (2001) Hyper-CK-aemia revisited. Neuromuscul Disord 11:163-164
8. Sunohara N, Takagi A, Nonaka I et al (1984) Idiopathic hyperCKemia. Neurology 34:544-547
9. Prelle A, Tancredi L, Sciacco M et al (2002) Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels. J Neurol 249:305-311
10. Brainin M, Barnes M, Baron JC et al (2004) Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations. Eur J Neurol 11:577-581
11. Saks VA, Lipina NV, Liulina IV et al (1976) Functional characterization of the creatine phosphokinase reactions in heart mitochondria and myofibrils. Biokhimiia 41:1460-1470
12. Stein W, Bohner J, Eggstein M, Lang H (1983) Creatine kinase variants. Report on the workshop conference of the German Society for Clinical Chemistry held on September 19 to 21, 1982, in Tubingen, FRG. J Clin Chem Biochem 21:859-876
13. Canalias F, Saco Y, Gella FJ (1995) Comparison of kits for the determination of creatine kinase activity in serum. Eur J Clin Chem Clin Biochem 33:535-539
14. Schumann G, Bonora R, Cerotti F et al (2002) IFCC primary reference procedures for the measurement of catalytic activity concentration of creatine kinase. Clin Chem Lab Med 40:635-642
15. Schumann G, Klauke R (2003) New IFCC reference procedures for the determination of catalytic activity concentrations of the five enzymes in serum: Preliminary upper reference limits obtained in hospitalized subjects. Clin Chem Acta 327:69-79
16. Wong ET, Cobb C, Humehara MK et al (1983) Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am J Clin Pathol 79:582-586
17. Worrall JG, Phongsathorn V, Hooper RJ, Paice EW (1990) Racial variation in serum creatine kinase unrelated to lean body mass. Br J Rheumatol 29:371-373
18. Gilboa N, Swanson JR (1976) Serum creatine phosphokinase in normal newborns. Arch Dis Child 51:283-285
19. Scheurbrandt G, Mortier W (1984) Voluntary newborn screening for Duchenne muscular dystrophy: A nationwide pilot program in West Germany. In: Serratrice G et al (eds) Neuromuscular diseases. Raven Press, New York, pp 33-35
20. Bundey S, Crawley JM, Edwards JH, Westhead RA (1979) Serum creatine kinase levels in pubertal, mature, pregnant and postmenopausal women. J Med Genet 16:117-121
21. Fukutake T, Hattori T (2001) Normalization of creatine kinase level during pregnancy in idiopathic hyperCKemia. Clin Neurol Neurosurg 103:168-170
22. Dop Bär P et al (1997) Symptoms of muscle damage. In: Salmons S (ed) Muscle damage. Oxford University Press, Oxford, pp 3-6
23. Nosaka K, Clarkson PM, Apple FS (1992) Time course of serum protein changes after strenuous exercise of the forearm flexors. J Lab Clin Med 119:183-188
24. Clarkson PM, Nosaka K, Braun B (1992) Muscle function after exercise-induced muscle damage and rapid adaptation. Med Sci Sports Exerc 24:512-520
25. Hagberg M, Michaelson G, Ortelius A (1982) Serum creatine kinase as an indicator of local muscular strain in experimental and occupational work. Int Arch Occup Environ Health 50:377-386
26. Hays AP, Gamboa ET (1994) Acute viral myositis. In: Engel AG, Franzini Armstrong C (eds) Myology: Basic and Clinical, Vol 2, 2nd edn. McGraw-Hill Inc, New York, pp 1399-1418
27. King JO, Zapf P (1972) A review of the value of creatine phosphokinase estimations in clinical medicine. Med J Aust 1:699-703
28. Swash M, Schwartz S, Carter ND et al (1983) Benign Xlinked myopathy with acanthocytes (McLeod Syndrome). Brain 106:717-733
29. Byrne MF, Razak AR, Leader MB et al (2002) Disabling osteomalacic myopathy as the only presenting feature of coeliac disease. Eur J Gastroenterol Hepatol 14:1271-1274
30. Ertekin V, Ayse Silimoglu M, Tan H, Kilicaslan B (2003) Rhabdomyolysis in celiac disease. Yansei Med J 44:328-330
31. Kozanoglu E, Basaian S, Goucu MK (2005) Proximal myopathy as an unusual presenting feature of celiac disease. Clin Rheumatol 24:76-78
32. Mercer DW (1977) Frequent appearance of creatine kinase isoenzyme BB in sera of critical care patients. Clin Chem 23:611-612
33. Nanji AA (1983) Serum creatine kinase isoenzymes: A review. Muscle Nerve 6:83-90
34. Layzer RB (1985) Interpretation of laboratory tests - serum enzymes. In: RB Layzer (ed) Neuromuscular manifestations of systemic disease. Davis Company, Philadelphia, pp 23-27
35. Paret G, Tirosh R, Ben-Zeev B et al (1995) Rhabdomyolysis due to hereditary torsion dystonia. Pediatr Neurol 13:83-84
36. Konikoff F, Halevy J, Theodor E (1985) Serum kinase after intramuscular injections. Postgrad Med J 61:595-598
37. Bank-Mikkelsen OK, Steiness E, Arnold E et al (1978) Serum diazepam and serum creatine kinase after intra-muscular injection of diazepam in two different vehicles. Acta Anaesthesiol Scand 67:91-95
38. Montero Perez FJ, Munoz Avila J, Berlango Jimenez A et al (1996) Increase of blood levels of creatine kinase following intramuscular injection. Med Clin 107:649-654
39. Chrissian SA, Stolov WC, Hongladarom T (1976) Needle electromyography: its effect on serum creatine phosphokinase activity. Arch Phys Med Rehabil 57:114-119
40. Pedinoff S, Sandhu RS (1978) Electromyography effect on serum creatine phosphokinase in normal individuals. Arch Phys Med Rehabil 59:27-29
41. Finsterer J, Mittendorfer B, Neuhuber W, Loscher WN (2002) Influence of disposable, concentric needle electrodes on muscle enzyme and lactate serum levels. J Electromyogr Kinesiol 12:329-337
42. Levin R, Pascuzzi RM, Bruns DE et al (1987) The time course of creatine kinase elevation following concentric needle EMG. Muscle Nerve 10:242-245
43. Suzuki S, Ichikawa K, Nagai M et al (1997) Elevation of serum creatine kinase during treatment with antithyroid drugs in patients with hyperthyroidism due to Graves disease. A novel side effect of antithyroid drugs. Arch Intern Med 157:693-696
44. Beyer IW, Karmali R, Demeester-Mirkine N et al (1998) Serum creatine kinase levels in overt and subclinical hypothyroidism. Thyroid 8:1029-1031
45. Rodolico C, Toscano A, Benvenga S et al (1998) Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism. Thyroid 8:1033-1038
46. Scott KR, Simmons Z, Boyer PJ (2002) Hypothyroid myopathy with strikingly elevated serum creatine kinase level. Muscle Nerve 26:141-144
47. Khaleeli AA, Griffith DG, Edwards RH (1983) The clinical presentation of hypothyroid myopathy and its relationship to abnormalities in structure and function of skeletal muscle. Clin Endocrinol 19:365-376
48. Giampietro O, Clerico A, Buzzigoli G et al (1984) Detection of hypothyroid myopathy by measurement of various serum muscle markers - myoglobin, creatine kinase, lactate dehydrogenase and their isoenzymes. Correlations with thyroid hormone levels [free and total] and clinical usefulness. Horm Res 19:232-242
49. Duyff RF, Van den Bosch J, Laman DM et al (2000) Neuromuscular findings in hypothyroid dysfunction: A prospective clinical and electrodiagnostic study. Neurol Neurosurg Psychiatry 68:750-755
50. Dugue A, Bagheri H, Lapeyre-Mestre M et al (2004) Detection and incidence of muscular adverse drug reactions: A prospective analysis from laboratory signals. Eur J Clin Pharmacol 60:285-292
51. Pasternak RC, Smith SC, Bayre-Merz CN et al (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 33:2337-2341
52. Hodel C (2002) Myopathy and rhabdomyolisis with lipidlowering drugs. Toxicol Lett 128:159-168
53. Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681-1690
54. Miller JAL (2005) Statins - challenges and provocations. Curr Opin Neurol 18:494-496
55. Leung NM, Ooi TC, McQueen MJ (2000) Use of statins and fibrates in hyperlipidemic patients with neuromuscular disorders. Ann Intern Med 32:418-419
56. Wortmann RL (2002) Lipid-lowering agents and myopathy. Curr Opin Rheumatol 14:643-647
57. Scelsa SN, Simpson DM, McQuistion HL et al (1996) Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 47:1518-1523
58. Kirby D, Ames D (2002) Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry 16:484-493
59. Goldenberg I, Jonas M, Thaler M, Grossman E (1997) Elevated levels of serum creatine kinase induced by hyponatraemia. Postgrad Med J 73:511-512
60. Saruta T, Suzuki H, Kawamura M, Itoh H (1985) Serum creatine phosphokinase levels during treatment with betaadrenoreceptor blocking agents. J Cardiovasc Pharmacol 7:805-808
61. Imai Y, Watanabe N, Hashimoto J et al (1995) Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers. Eur J Clin Pharmacol 48:29-34
62. Imataka K, Seki A, Takahashi N, Fujii J (1981) Elevation of serum creatine phosphokinase during pindolol treatment. Tohoku J Exp Med 133:363-364
63. Itoh H, Jingu Y, Numakami K, Saruta T (1993) Effects of beta-blocking agents on the release of various enzymes in muscular tissues. Kitasato Arch Exp Med 65[Suppl]:57-63
64. Goulden V, Layton AM, Cunliffe WJ (1994) Long term safety of Isotretinoin as a treatment for acne vulgaris. Br J Dermatol 131:360-363
65. Guttman-Yassky E, Hayek T, Muchnik L, Bergman R (2003) Acute rhabdomyolysis and myoglobinuria associated with isotretinoin treatment. Int J Dermatol 42:499-500
66. Landau M, Mesterman R, Ophir J et al (2001) Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol 81:350-352
67. Litman RS, Rosenberg H (2005) Malignant hyperthermia update on susceptibility testing. JAMA 293:2918-2924
68. Allen GC, Larach MG, Kunselman AR (1998) The sensitivity and specificity of the caffeine-halothane contracture test: A report from the North American Malignant Hyperthermia Registry. Anesthesiology 88:579-588
69. Weglinski MR, Wedel DJ, Engel AG (1997) Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 84:1038-1041
70. Brewster LM, de Visser M (1988) Persistent high plasma CK: Fourteen studied in retrospect. Acta Neurol Scand 77:60-63
71. Kleppe B, Reimers CD, Altmann C, Pongratz DE (1995) Findings in 100 patients with idiopathic increase in serum creatine kinase activity. Med Klin 90:623-627
72. Joy JL, Oh SJ(1989) Asymptomatic hyper-CK-emia: An electrophysiologic and histopathologic study. Muscle Nerve 12:206-209
73. Simmons Z, Peterlin BL, Boyer PJ, Towfighi J (2003) Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle Nerve 27:242-244
74. Musumeci O, Rodolico C, Nishino I et al (2005) Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene. Neuromuscul Disord 15:409-411
75. Hoffman EP, Clemens PR (1996) HyperCKemic, proximal muscular dystrophies and the dystrophin membrane cytoskeleton, including dystrophinopathies, sarcoglycanopathies, and merosinopathies. Curr Opin Rheumatol 8:528-538